Jan 27, 2025 · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up 5.3% at $7.48 in early trading.

Jan 21, 2025 · Biogen’s offer, at about $469 million, effectively assigns Sage a negative value because the Massachusetts biotech had about $569 million in cash and equivalents at the end of September.

Jan 10, 2025 · No Shareholder Action Required at This Time. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2025-- Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law.. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted that it “is seeking preliminary injunctive relief to enforce a standstill agreement and a ...

Jan 27, 2025 · Sage Therapeutics Inc. is looking for a deal — but it’s not interested in the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.. The Cambridge ...

Jan 28, 2025 · BIIB's Recent Offer to Acquire SAGE. Earlier this month, Biogen made an acquisition offer to buy the remaining shares of SAGE that it does not already own for $7.22 per share. The offer price ...

Jan 10, 2025 · Company Board Concludes the Proposal Significantly Undervalues Sage and Believes it is Not in the Best Interest of Shareholders. ... (“Biogen”) on January 10, 2025, to acquire all outstanding shares of Sage not already owned by Biogen for $7.22 per share. The Company has not set a timetable for the review process, nor has it made any ...

Jan 10, 2025 · Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.

Sep 26, 2024 · (RTTNews) - Sage Therapeutics, Inc. (Sage) announced Thursday that Biogen Inc. (BIIB) has terminated its rights under the collaboration and license agreement specific to the SAGE-324...

Jan 27, 2025 · Earlier this month, Biogen offered to purchase Sage’s outstanding shares for an equity value of about $469 million. The drugmaker already owns 10.2% of Sage through a collaboration agreement the ...